Shots:
- Silexion reported preclinical data of SIL-204 (siRNA agent) + 5-fluorouracil + irinotecan & SIL-204 + gemcitabine combinations in KRAS G12D mutated human pancreatic tumor cell lines
- The data demonstrated a reduction in cancer cell confluence in contrast to 1L CT agents alone, where SIL-204 + 5-fluorouracil + irinotecan achieved reduction after 3 days
- Silexion will start the toxicology studies for SIL-204 in the forthcoming mos. & advance it in P-II/III trials in H1’26 for locally advanced pancreatic cancer (LAPC), plus initiate preclinical studies in colorectal cancer models
Ref: Globenewswire | Image: Silexion Therapeutics
Related News:- Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
